The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chronic Disease Medicat...
Medicare drug price negotiations are transforming access to affordable healthcare for seniors, and if you're wondering how these negotiations will lower costs for high-expense cancer and chronic disease treatments, the answer is clear. Starting January 1, 2027, the Centers for Medicare & Medi...
Enhancing Efficiency in FAST-EU Clinical Trials: A New Era for Biomedical Research
Advancing EU Clinical Trial Efficiency Through FAST-EU Trials
The FAST-EU clinical trials initiative, launched by a coalition of National Competent Authorities (NCAs) and Ethics Committees across the European Union/Europ...
Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management
Advancements in CGM for Type 2 Diabetes Management
A recent JAMA Insights article, explores the integration of continuous glucose monitoring as a complementary tool to traditional hemoglobin A1c (HbA1c) an...